-
公开(公告)号：US11033537B2
公开(公告)日：2021-06-15
申请号：US16915562
申请日：2020-06-29
IPC分类号： A61K31/444 , C07K16/28 , A61K39/395 , A61K45/06 , A61P35/00 , A61K39/00
摘要： The present invention provides, inter alia, a composition containing a compound of formula (I): or a pharmaceutically acceptable salt thereof, optionally, in combination with at least one immune checkpoint inhibitor compound. Kits containing the composition, and methods of using the composition for ameliorating or treating the effects of a disease such as a cancer, in a subject, are also provided herein.
-
公开(公告)号：US20210085663A1
公开(公告)日：2021-03-25
申请号：US16613480
申请日：2018-05-15
发明人： Gary DeCrescenzo , Dean Welsch , Saurabh Saha
IPC分类号： A61K31/4439 , A61K31/506 , A61K31/444 , A61K31/5377 , A61K31/4985 , A61K38/48 , A61K31/122 , A61K31/4184 , A61K31/4045 , A61K31/365 , A61K31/437 , A61K31/675 , A61K31/517 , A61K31/44 , C12N15/113 , A61K31/519 , A61K31/343 , A61K31/325 , A61K31/167 , A61K31/166 , A61K31/18 , A61K45/06 , A61K39/395 , A61K31/131 , A61K31/513 , A61K31/198 , A61K31/196 , A61K31/175 , A61K31/7028 , A61K33/243 , A61K38/45 , A61K51/00 , A61K38/21 , A61K38/20 , A61K38/19 , A61K35/74 , A61K31/4168 , A61K31/4164 , A61K31/53 , A61K31/202 , A61P35/00 , C12Q1/6886
摘要： The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which harbors an atypical BRAF mutation (i.e. a non-V600E/K BRAF mutation), comprising an ERK inhibitor. Also provided are methods for identifying a subject having an atypical BRAF mutant cancer who would benefit from therapy comprising an ERK inhibitor.
-
公开(公告)号：US20200297730A1
公开(公告)日：2020-09-24
申请号：US16856849
申请日：2020-04-23
IPC分类号： A61K31/519 , A61K31/4439 , A61K31/506 , A61K45/06 , C07D401/04
摘要： The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method comprises administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.
-
公开(公告)号：US10758614B2
公开(公告)日：2020-09-01
申请号：US15317086
申请日：2015-06-09
申请人： BIOMED VALLEY DISCOVERIES, INC. , THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
发明人： Saurabh Saha , Xiaoyan M. Zhang , Dimiter Dimitrov , Zhongyu Zhu , Brad St. Croix , Enrique Zudaire
IPC分类号： A61K39/395 , A61K31/337 , A61K31/4745 , A61K31/704 , C07K16/30 , C07K16/28 , A61K31/505 , A61K31/415 , A61K45/06 , C07K16/22 , A61K47/68 , A61K39/00
摘要： The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a topoisomerase inhibitor; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody contains: (i) a heavy chain variable region (VH), which includes an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7; and (ii) a light chain variable region (VL), which includes an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein.
-
公开(公告)号：US10738027B2
公开(公告)日：2020-08-11
申请号：US16227820
申请日：2018-12-20
发明人： Gary DeCrescenzo , Dean Welsch , Petinka I. Vlahova , Stephan X. M. Boerrigter , Alexander Aronov , Ali Keshavarz-Shokri , Alexander N. Scangas , Kathy Stavropoulos , Benjamin Littler , Irina Nikolaevna Kadiyala , Rossitza Gueorguieva Alargova
IPC分类号： C07D401/04 , A61K45/06 , A61P35/00 , A61K31/4439
摘要： The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
-
公开(公告)号：US10716782B2
公开(公告)日：2020-07-21
申请号：US16692560
申请日：2019-11-22
IPC分类号： A61K31/444 , C07K16/28 , A61K39/395 , A61K45/06 , A61P35/00 , A61K39/00
摘要： The present invention provides, inter alia, a composition containing a compound of formula (I): or a pharmaceutically acceptable salt thereof, optionally, in combination with at least one immune checkpoint inhibitor compound. Kits containing the composition, and methods of using the composition for ameliorating or treating the effects of a disease such as a cancer, in a subject, are also provided herein.
-
公开(公告)号：US10668055B2
公开(公告)日：2020-06-02
申请号：US15105904
申请日：2014-12-19
IPC分类号： A61K31/4439 , A61K31/437 , A61K31/506 , A61K45/06 , A61K31/519 , A61K31/555 , A61K31/5377 , A61K31/517 , A61K31/428 , A61K31/44
摘要： The present invention provides, inter alia, methods of treating or ameliorating the effects of a cancer in a subject. The methods include administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a type 1 RAF inhibitor (such as dabrafenib) or another RAF inhibitor (such as regorafenib) or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Also provided are pharmaceutical compositions and kits for treating or ameliorating the effects of a cancer in a subject.
-
公开(公告)号：US10604583B2
公开(公告)日：2020-03-31
申请号：US15699419
申请日：2017-09-08
申请人： THE UNITED STATES OF AMERICA, AS PRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , BIOMED VALLEY DISCOVERIES, INC.
发明人： Rimas J. Orentas , Zhongyu Zhu , Crystal L. Mackall , Dimiter S. Dimitrov , Bradley St. Croix , Saurabh Saha
IPC分类号： C07K16/30 , C07K16/28 , G01N33/574
摘要： Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
-
公开(公告)号：US10434174B2
公开(公告)日：2019-10-08
申请号：US15317084
申请日：2015-06-09
申请人： BIOMED VALLEY DISCOVERIES, INC. , THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
发明人： Saurabh Saha , Xiaoyan M. Zhang , Dimiter Dimitrov , Zhongyu Zhu , Brad St. Croix , Enrique Zudaire
IPC分类号： A61K39/395 , A61K31/555 , C07K16/22 , C07K16/28 , C07K16/30 , A61K31/282 , A61K33/24 , A61K39/00
摘要： Methods, pharmaceutical compositions, and kits for treating a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a platinum agent; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof.
-
公开(公告)号：US10183927B2
公开(公告)日：2019-01-22
申请号：US15598181
申请日：2017-05-17
发明人： Gary DeCrescenzo , Dean Welsch , Petinka I. Vlahova , Stephan X. M. Boerrigter , Alexander Aronov , Ali Keshavarz-Shokri , Alexander N. Scangas , Kathy Stavropoulos , Benjamin Littler , Irina Nikolaevna Kadiyala , Rossitza Gueorguieva Alargova
IPC分类号： C07D401/04 , A61K45/06 , A61P35/00 , A61K31/4439
摘要： The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
-
-
-
-
-
-
-
-
-
搜索结果
83 条记录 (耗时 0.025 秒)
